Clinical Trial Update: A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases [Phase 2]

View source ↗

Summary

This randomized Phase II trial evaluates osimertinib with or without stereotactic radiosurgery (SRS) in patients with EGFR-mutant non-small cell lung cancer and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Trans Tasman Radiation Oncology Group | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED